Kornimate/medical-research-clean huggingface dataset:
carer skills training for inpatients with anorexia nervosa (icask)

Conditions: Anorexia Nervosa

Summary: to improve treatment for patients with severe anorexia nervosa admitted for inpatient care, and to help their families. inpatients and their families will be offered a novel intervention which includes multimedia training materials. these materials provide guidance in how families can provide support to maintain and build on changes made during inpatient care

problem to be solved: hospital episode statistics reveal that admissions for anorexia nervosa are increasing \[1\]. admission restores nutrition in a timely manner \[2\], but psychosocial problems remain and relapse following discharge is common \[3\]. the mortality post discharge is high \[4\]. we have found that relapse and bed use post discharge are reduced by a parenting intervention giving the family skills to manage eating disorder behaviours \[5\]. innovation: through a process of co-production, in collaboration with service users and their families, we have developed tools exemplifying emotional coaching behaviour change strategies for patients and their carers (texts, dvds and podcasts; icask programme). these aim of these tools is to improve the transition to outpatient care. these are hosted on a user-friendly, confidential and nhs-compliant platform.

Eligibility criteria:
inclusion criteria: * aged 17 or over * dsm-5 diagnosis of anorexia nervosa with a body mass index (bmi) of \< 18.5 kg/m2 exclusion criteria: * insufficient knowledge of english * severe mental or physical illness needing treatment in its own right (e.g. psychosis or diabetes mellitus)
outcomes of a new trans-epithelial photorefractive keratectomy (streamlight prk) compared to conventional prk procedures

Conditions: Myopia ≤ -6 Diopters or Myopic Astigmatism ≤ -4 Diopters

Summary: photorefractive keratectomy (prk) involves mechanical or alcohol assisted debridement of the epithelium that leads to potential basement membrane (bm) injury ,with resultant more significant haze and pain compared to laser assisted epithelial removal known as 2 step trans-epithelial prk (ptk-prk). our study is focusing on comparing the outcomes of the conventional 2 step trans-epithelial ptk-prk to the new single step trans-epithelial prk (streamlight prk, alcon lab, tx, usa).

photorefractive keratectomy (prk) is nowadays one of the commonest refractive procedures in laser vision correction (lvc). prk differs from laser in situ keratomileusis (lasik) in that it's a flapless procedure involving the removal of corneal epithelium with different techniques including manual removal , alcohol assisted removal or excimer laser assisted removal with phototherapeutic keratectomy (ptk). mechanical or alcohol assisted debridement of the epithelium may lead to potential basement membrane (bm) injury ,with resultant more significant haze and pain compared to laser assisted epithelial removal known as 2 step trans-epithelial prk (ptk-prk). single step trans-epithelial prk allows removing the epithelium and stroma in a single step with a single ablation profile. previous studies paid particular attention for comparing the 2 step ptk-prk procedure or the new single step prk procedure to the conventional prk procedures involving epithelial removal whether manual or alcohol assisted. the aim of this study is to focus on comparing the different outcomes of the new single step trans-epithelial prk (streamlight technology) versus the routine 2 step ptk-prk in terms of postoperative vision, epithelial healing, pain scoring and haze evaluation.

Eligibility criteria:
* inclusion criteria: candidates for laser vision correction (lvc) with 1. myopia up to -6 diopters 2. myopic astigmatism up to -4 diopters 3. corneal thinnest location ≥ 500 um and a residual stromal bed ≥ 300um. * exclusion criteria 1. patients not candidates for lvc. 2. hyperopic patients. 3. systemic disease that contraindicates lvc. 4. intra- or post-operative complications.

Keywords: photorefractive keratectomy prk phototherapeutic keratectomy ptk trans-epithelial prk laser vision correction lvc
extra time on brazilian college level exam for students with and without adhd

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: standardized tests such as the scholastic aptitude test (sat) and the brazilian national high school exam (enem) give more time for students with attention deficit and hyperactivity disorders (adhd) to complete the exam. the goal of this study is to find out if giving students with adhd more time on tests actually helps them. additionally, the research aims to find out if more time helps students without adhd too or not, or even if it only helps students with certain traits.

initially, the participants of this study will fill out forms and questionnaires online. then, they will go through a psychiatric evaluation, where they will talk to a psychiatrist, and neuropsychological testing, where they will do some mental activities. later on, they will do a mock test of the enem, with and without extra time.

Eligibility criteria:
inclusion criteria: * brazilian citizen; * planing to participate in college-entry standardized tests (enem, vestibulares); exclusion criteria: * medical condition and/or disability that may hinder the neuropsychological testing; * intelligence quotient (iq) lower than 80; * psychotic disorders, bipolar disorders, current moderate or severe depressive episode, suicide risk, autism spectrum disorders, learning disabilities.

Keywords: extended time academic test performance academic achievement neuropsychological testing cognitive function
study to evaluate the safety, tolerability, and efficacy of vesatolimod in combination with tenofovir disoproxil fumarate (tdf) in adults with chronic hepatitis b (chb) infection who are currently not being treated

Conditions: Chronic Hepatitis B

Summary: the primary objectives of this study are to evaluate the safety, tolerability, and efficacy of vesatolimod (formerly gs-9620) in adults with chronic hepatitis b (chb) infection who are currently not being treated.


Eligibility criteria:
key inclusion criteria: * adult males or females between the ages of 18-65 * chronic hepatitis b virus (hbv) infection * hbv deoxyribonucleic acid (dna ) ≥ 2000 iu/ml at screening key exclusion criteria: * extensive bridging fibrosis or cirrhosis * received oral antiviral treatment for hbv or prolonged therapy with immune-modulators or biologics within 3 months of screening * co-infection with hepatitis c virus (hcv), human immunodeficiency virus (hiv) or hepatitis d virus (hdv) * chronic liver disease other than hbv * lactating or pregnant females or those that wish to become pregnant during the course of the study note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: hbv hepatitis liver disease
a pharmacokinetic (pk) study of three types of e0302 sustained release (sr) tablets compared with e0302 immediate release (ir) tablet under fed conditions in healthy participants

Conditions: Healthy Subjects

Summary: to assess the pk and safety after administration of three types of e0302 sr tablets (sr1, sr2, sr3) and e0302 ir tablet.


Eligibility criteria:
inclusion criteria: participants must meet all of the following criteria to be included in this study: 1. body mass index (bmi) of 18 to 30 kilogram per meter square \[kg/m2\], inclusive at screening exclusion criteria: participants who meet any of the following criteria will be excluded from this study: 1. history of drug or alcohol dependency or abuse within the 2 years before screening, or those who have a positive urine drug test or breath alcohol test at screening or baseline 2. subjects who contravene the restrictions on concomitant medications, food and beverages 3. currently enrolled in another clinical study or used any investigational drug or device within 3 months preceding informed consent

Keywords: e0302 healthy subjects e0302 sr tablet e0302 ir tablet
treatment of single maxillary gingival recession with loss of inter-dental attachment. a randomized controlled clinical trial

Conditions: Gingival Recession

Summary: background: the aim of this randomized clinical trial (rct) was to evaluate the adjunctive benefit of connective tissue graft (ctg) to coronally advanced flap (caf) for the treatment of gingival recession associated with inter-dental clinical attachment loss equal or smaller to the buccal attachment loss (rt2). material and methods:the patients were randomly assigned to caf+ctg (test group) or to caf alone (control group). measurements were performed by a blind and calibrated examiner. outcome measures included complete root coverage (crc), recession reduction (recred), root coverage esthetic score (res), intra-operative and post-operative morbidity, and root sensitivity.


Eligibility criteria:
inclusion criteria: * smoking \< 20 cigarettes/day. * full-mouth plaque score (fmps) and full-mouth bleeding score (fmbs) \< 15% (measured at four sites per tooth). * presence of at least one rt2 (cairo et al. 2011) buccal gingival recession \> 2 mm of depth * only gingival recessions localized at upper central and lateral incisors, canine, and first and second pre-molars associated with aesthetic problems and/ordental hypersensitivity were considered. * presence of an identifiable cej exclusion criteria: * systemic diseases or pregnancy. * systemic antibiotic therapy in the last 6 months. * active periodontal disease with sites showing probing depth \>4 mm.
ketodex for emergence delirium in children undergoing outpatient strabismus surgery

Conditions: Emergence Delirium; Strabismus

Summary: strabismus surgery for children is a very common procedure, with a high incidence of emergence delerium in the recovery room. a combination of intravenous ketamine/dexmedetomidine, or ketodex, has been previously shown to reduce emergence delerium in children undergoing adenotonsillectomy. here, we study its application in strabismus surgery.


Eligibility criteria:
inclusion criteria: * asa i/ii children undergoing outpatient strabismus surgery exclusion criteria: * anything not meeting the above
reference curve on bone mineral density in men

Conditions: Bone Mineral Density; Grip Strength; Physical Performance

Summary: in men, the hope of lower life, the absence of equivalent of menopause and the existence of a higher peak bone mass are the three factors that explain the lower incidence of osteoporosis in men.


Eligibility criteria:
inclusion criteria: * male * aged between 20 and 30 years * caucasians exclusion criteria: * lack of express consent * pieces of metal or plastic parts in field * diseases which cause technical difficulties for the correct evaluation of the hip and spine (severe dysplasia, hip surgery or lumbar spine) * adult protect buy the law
antibiotic therapy and antacids in patients with malt lymphoma of the stomach

Conditions: Lymphoma

Summary: rationale: antibiotic therapy and antacids are used to treat helicobacter pylori infection of the stomach. these treatments may also have an effect on gastric malt lymphoma of the stomach. purpose: phase ii trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with malt lymphoma of the stomach.

objectives: i. evaluate the response of gastric lymphoma of mucosa-associated lymphoid tissue (malt) to treatment for helicobacter pylori infection with antibiotics (amoxicillin, clarithromycin, tetracycline, and metronidazole) and with gastric acid inhibitors (omeprazole and bismuth subsalicylate). ii. correlate response with endoscopic tumor grade and clinical and pathological parameters. iii. assess the incidence of h. pylori infection in patients with gastric malt lymphoma. outline: all patients are treated on regimen a; those receiving tetracycline on regimen a are switched to regimen b for their second course; those receiving amoxicillin for their first course receive tetracycline for their second course. regimen a: antibiotic therapy with gastric acid inhibition. amoxicillin (or tetracycline in penicillin-allergic patients); clarithromycin; with bismuth subsalicylate; omeprazole. regimen b: antibiotic therapy with gastric acid inhibition. tetracycline; metronidazole, metro, nsc-50364; with bismuth subsalicylate; omeprazole. projected accrual: 75 patients will be entered over 3 years.

Eligibility criteria:
disease characteristics: suspected gastric lymphoma or documented gastric lymphoma of mucosa-associated lymphoid tissue (malt) that is stage ie gastric malt lymphoma with perigastric lymph nodes identified on endoscopic ultrasound eligible at mdacc and houston va medical center only no indication for expeditious treatment with chemotherapy, radiotherapy, or surgery based on clinical condition, underlying illness, or tumor stage patient characteristics: age: 18 to 80 performance status: not specified hematopoietic: not specified hepatic: not specified renal: not specified other: no contraindication to endoscopy or biopsy no pregnant or nursing women adequate contraception required of fertile patients prior concurrent therapy: no concurrent chemotherapy or radiotherapy

Keywords: antibiotic treatment gastric malt lymphoma stage i marginal zone lymphoma extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue
integrated coronary multicenter imaging registry

Conditions: Coronary Artery Disease

Summary: the coronary images of selective angiography and optical coherence tomography with ffr(fractional flow reserve) values of the intermediate lesions (40-70% stenosis) will be prospectively registered.

the patients with intermediate lesions after ct angiography and invasive coronary angiography will be screened, and optical coherence tomography, ffr and selective ct angiography will be performed. the coronary images and ffr values will be registered, and the patients will be followed-up up to 2 years to investigate the adverse clinical events.

Eligibility criteria:
inclusion criteria: * patients who underwent coronary ct angiography because of chest pain * patients who need oct or ffr evaluation because of intermediate lesions according to invasive angiography (diameter stenosis of 40-70%) * age: 20-80 yrs * patients who consent and fully understand the protocol * patients who consent the clinical follow-up * patients who can be followed-up exclusion criteria: * patients who had contrast allergy * patients who had unstable blood pressure needing the vasopressors * patients who had severe left ventricular function (left ventricular ejection fraction\<30%) * chronic kidney disease who had cr level of greater than 2.0 mg/dl * patients whose expected survival is less than 12 months * patients who had a severe valvular disease
microbial infection and amr in hospitalized patients with covid 19

Conditions: Covid19

Summary: to detect microbial infection and amr associated with covid 19 infection. to correlate risk factors of covid 19 patients with microbial infections and their effects on disease.

the most common type of infection among icu patients was bacterial or fungal pneumonia; bloodstream and urinary tract infections were also noted. organisms cultured from patients included pandrug-resistant acinetobacter baumannii, klebsiella pneumoniae carbapenemase-producing k. pneumoniae, extended-spectrum β-lactamase (esbl)- producing k. pneumoniae, esbl-producing pseudomonas aeruginosa, enterobacter cloacae, serratia marcescens, aspergillus fumigatus, aspergillus flavus, candida albicans, and candida glabrata .

Eligibility criteria:
inclusion criteria: * patients with covid infection exclusion criteria: * patients without covid 19
the safety and efficacy of collagen injection in patients with plantar fasciitis

Conditions: Plantar Fasciitis

Summary: the primary objective of this study is to evaluate the safety and efficacy of collagen injection in patients with plantar fasciitis

this study is an open-trial study. sixty subjects will be participated in it. the study will be explained to the subjects and they voluntarily agreed to participate in it. their eligibility to participate in the study will be checked, and the patient will receive collagen or a placebo (normal saline) in the plantar facia through randomization. they will be asked to follow the guidelines of the investigators during the study and to visit the hospital seven times, including for screening and the date of re-injection. . at each visit, the subjects undergo a vas, a clinical laboratory tests, and a physical exam to evaluate the safety and efficacy of regenseal. (\*re-injection could be maximum 2times at visit2 and 3, one week apart based on the investigator's judgment after the initial injection. if the subject gets injection on the screening date, the total number of his or her visits will be six.)

Eligibility criteria:
inclusion criteria: - 1. patient with chronic plantar fasciitis (patients who had been diagnosed with plantar fasciitis but had not been responsive to non-invasive treatment for more than three months (non-invasive treatments include drugs, physiotherapy shock wave, or stretching) 2. patients who are able to complete the questionnaires related to the safety and efficacy of the study drug and who read and understood the guidelines 3. patients who agreed to maintain the medication dose during the study period if they need to keep taking it. (excluded anti-inflammatory analgesic drug for pain after the injection.) 4. patients who agreed not to use physical therapy or shock wave during the study period. 5. patients or their representative (for adults), or patients and their parent/guardian (for minors), who agreed to participate in the study and signed the informed consent form exclusion criteria: * 1. if patients or their families suffer from or have ever suffered from an autoimmune disease. 2. patients who have ever suffered an anaphylactic reaction. 3. patients who have ever suffered hypersensitivity to an implant. 4. patients with a history of allergy to porcine or bovine protein. 5. patients with rheumatoid arthritis. 6. patients with ankylosing spondylitis. 7. patients who are suspected of having spinal deformity with a negative serum test 8. subjects who are pregnant and/or breast-feeding and/or plan a pregnancy. 9. subjects with psychiatric disorders who are considered inappropriate to participate in this trial by the principal investigator.

Keywords: collagen collagen injection plantar fasciitis
removal of mtdna in plasma by continous venovenous hemofiltration in sepsis

Conditions: Intensive Care Unit

Summary: the plasma level of mtdna in sepsis is affected by continous venovenous hemofiltation（cvvh）

continous renal replacement therapy （crrt）has become routine for patients with chronic renal failure ，aki，fliud overload as well as oliguria in icu .in clinical patients ，continous venovenous hemofoiltration （cvvh）is actually the method of chioce for crrt in critically ill and hemodynamic instable patients .cvvh has significant beneficial effects on removing inflammatory cytokines ，improving oxygen index，increasing cardiac index and regulating immune dysfuntion .

Eligibility criteria:
inclusion criteria: adult septic patients undergoing crrt exclusion criteria: 1. missing vists 2. transplatation 3. cancer 4. aquired immunodeficiency syndrome

Keywords: mitochondrial dna sepsis continous venovenous hemofiltation intensive care unit
computerized cognitive training for patients with epilepsy

Conditions: Epilepsy

Summary: this is a study on the effectiveness of computerized cognitive training for treatment of memory disorders in patients with epilepsy. participants will be recruited from patients referred for neuropsychological assessment through the nyu comprehensive epilepsy center's inpatient and outpatient services. individuals meeting inclusion criteria will be screened for the presence of memory disturbance (defined by results of neuropsychological testing) and lack of exposure to any previous form of computerized cognitive training. all eligible subjects will be provided with an account for lumosity with instructions to complete training modules 5 days per week for a total of 8 consecutive weeks. outcomes will be evaluated through changes on the neuropsychological test battery.


Eligibility criteria:
inclusion criteria: * documented diagnosis of epilepsy based on medical records. the records will be reviewed by the pi and the approved study personnel to confirm that a diagnosis of epilepsy has been made. * presence of memory disturbance, as defined by an immediate or delayed memory index score \< 85 on the repeatable battery for the assessment of neuropsychological status (rbans) * availability of a home computer and internet for access to the computer training program. exclusion criteria: * full scale iq \< 80, as assessed by an appropriate wechsler scale (wais-iv or wasi-ii). * epilepsy surgery within 8 weeks of the beginning of the trial. * history of chronic progressive neurologic or neurodegenerative illnesses (e.g., alzheimer's disease, multiple sclerosis, primary or metastatic malignancy). patients with headache or migraine are not excluded. * history of axis i psychiatric illness with psychotic features. (e.g., schizophrenia or bipolar disorder). patients with depression or anxiety (treated or untreated) without psychotic features are not excluded. * visual or auditory impairment, which precludes participation in part, or all of the testing or computer training. * english as a first language will not be required, but participants must have either received some of their schooling in english or used english in their work for \>10 years. * previous exposure (\> one week) to lumosity or a similar computerized training program.
avatrombopag for the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy in patients with lymphoma

Conditions: Thrombocytopenia; Cytarabine Causing Adverse Effects in Therapeutic Use; Lymphoma

Summary: this phase 2 trial studies the efficacy and safety of avatrombopag for the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy in patients with lymphoma


Eligibility criteria:
inclusion criteria: * histologically confirmed lymphoma; * patients are scheduled to receive cytarabine-based chemotherapy including ara-c at dose of 4g/m2. * eastern cooperative oncology group (ecog) of 0-1; * proper functioning of the major organs: 1) the absolute value of neutrophils (\>1.5×10\^9/l); platelet count (\> 100×10\^9/l); hemoglobin (\> 90 g/l); 2) serum total bilirubin \< 1.5 times uln; aspartate aminotransferase (ast), alanine aminotransferase (alt) \< 3 times uln;3) serum creatinine \<1.5 times upper limit normal (uln) ; 4) coagulation function: international normalized ratio (inr), prothrombin time (pt)\< 1.5 times uln * able to use oral drugs * patients volunteer to sign an informed consent * life expectancy \> 3 months; * contraceptives are used exclusion criteria: * thrombocytopenia unrelated to chemotherapy during six months before screening, including but not limited to hypersplenism, infection and hemorrhage. * in addtion to cit caused by lymphoma and chemotherapy,patients also suffer from other blood diseases including all, aml, myeloid neoplasms, mds, myeloproliferative disorders, mm; * a thrombosis of a coronary artery or vein developed during three months before screening; * haemorrhage with severe clinical symptoms, such as gastrointestinal and cerebral hemorrhage; * platelet transfusion during two days before randomization; * allergic to avatrombopag; * participation in any other research about novel agents or devices; * pregnant or breastfeeding women; * researchers consider it unsuitable for patients to participate in this study.